3.236.143.154
dgid:
enl:
npi:0
-Advertisement-

Dry Eye

Study finds long-term cyclosporine ophthalmic solution is well-tolerated for dry eye disease

Results from the ESSENCE‑2 open-label extension (OLE) clinical study highlight the sustained safety and efficacy of cyclosporine ophthalmic solution 0.1% (VEVYE®) for the treatment of dry eye disease. The phase 3, prospective, multicenter, OLE included 202 patients using cyclosporine ophthalmic solution 0.1% in each eye twice daily for 1 year....

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-